Free Trial
→ Trump’s Exec Order #14154 could be a “Millionaire-Maker” (From Paradigm Press) (Ad) Buy RMD Stock  Free RMD Stock Alerts

ResMed (RMD) Financials

ResMed logo
$250.46 -1.22 (-0.49%)
As of 09:55 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for ResMed

Annual Income Statements for ResMed

This table shows ResMed's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 6/30/2015 6/30/2016 6/30/2017 6/30/2018 6/30/2019 6/30/2020 6/30/2021 6/30/2022 6/30/2023 6/30/2024
Net Income / (Loss) Attributable to Common Shareholders		 353 352 342 316 405 622 475 779 898 1,021
Consolidated Net Income / (Loss)		 353 352 342 316 405 622 475 779 898 1,021
Net Income / (Loss) Continuing Operations		 353 352 342 316 405 622 475 779 898 1,021
Total Pre-Tax Income 		436 440 419 521 519 733 884 960 1,102 1,265
Total Operating Income		 409 429 426 542 579 810 904 1,000 1,132 1,320
Total Gross Profit		 1,011 1,066 1,202 1,335 1,494 1,718 1,839 2,024 2,356 2,655
Total Revenue		 1,679 1,839 2,067 2,340 2,607 2,957 3,197 3,578 4,223 4,685
Operating Revenue		 1,679 1,839 2,067 2,340 2,607 2,957 3,197 3,578 4,223 4,685
Total Cost of Revenue		 668 772 865 1,005 1,113 1,239 1,358 1,554 1,867 2,030
Operating Cost of Revenue		 668 772 865 1,005 1,113 1,239 1,358 1,554 1,867 2,030
Total Operating Expenses		 602 638 776 793 915 908 935 1,024 1,224 1,335
Selling, General & Admin Expense		 479 488 554 600 645 677 670 738 874 917
Research & Development Expense		 115 119 144 155 181 202 225 254 288 308
Amortization Expense		 8.67 24 47 19 32 30 31 31 42 47
Restructuring Charge		 0.00 6.91 22 18 9.40 0.00 8.67 1.86 20 64
Total Other Income / (Expense), net		 27 11 -7.06 -21 -60 -77 -20 -40 -30 -55
Interest & Investment Income		 26 17 17 16 -14 -25 -11 -31 -55 -48
Other Income / (Expense), net		 6.25 4.96 4.10 -8.54 -11 -12 15 -9.01 24 -7.54
Income Tax Expense		 83 87 76 206 114 111 409 181 204 244
Basic Earnings per Share		 $2.51 $2.51 $2.42 $2.21 $2.83 $4.31 $3.27 $5.34 $6.12 $6.94
Weighted Average Basic Shares Outstanding		 140.47M 140.24M 141.36M 142.76M 143.11M 144.34M 145.31M 146.07M 146.77M 147.02M
Diluted Earnings per Share		 $2.47 $2.49 $2.40 $2.19 $2.80 $4.27 $3.24 $5.30 $6.09 $6.92
Weighted Average Diluted Shares Outstanding		 142.69M 141.67M 142.45M 143.99M 144.48M 145.65M 146.45M 147.04M 147.46M 147.55M
Weighted Average Basic & Diluted Shares Outstanding		 140.60M 140.40M 141.40M 142.80M 143M 144.90M 145.68K 146.42M 147.07M 146.93M
Cash Dividends to Common per Share		 $1.12 $1.20 $1.32 $1.40 $1.48 $1.56 $1.56 $1.68 $1.76 $1.92

Quarterly Income Statements for ResMed

This table shows ResMed's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 210 225 233 230 219 209 300 292 311 345 365
Consolidated Net Income / (Loss)		 210 225 233 230 219 209 300 292 311 345 365
Net Income / (Loss) Continuing Operations		 210 225 233 230 219 209 300 292 311 345 365
Total Pre-Tax Income 		262 274 289 277 272 259 375 358 383 418 418
Total Operating Income		 276 280 301 275 289 275 375 381 387 417 426
Total Gross Profit		 541 580 618 617 600 647 693 716 717 751 766
Total Revenue		 950 1,034 1,117 1,122 1,102 1,163 1,197 1,223 1,225 1,282 1,292
Total Cost of Revenue		 409 454 499 505 502 516 504 508 507 531 525
Operating Cost of Revenue		 409 454 499 505 502 516 504 508 507 531 525
Total Operating Expenses		 265 300 317 342 311 372 318 334 330 334 340
Selling, General & Admin Expense		 194 212 228 240 223 222 230 242 239 242 245
Research & Development Expense		 63 70 76 78 76 74 77 81 80 81 84
Amortization Expense		 7.95 9.56 12 12 12 12 11 11 11 11 11
Total Other Income / (Expense), net		 -14 -6.50 -11 1.54 -17 -16 0.84 -23 -3.82 1.08 -8.58
Interest & Investment Income		 -2.03 -2.83 -0.18 -50 -19 -13 0.44 -45 0.96 1.08 0.34
Other Income / (Expense), net		 -4.78 6.66 3.85 19 2.05 -2.57 11 -18 -3.12 0.78 -9.70
Income Tax Expense		 51 49 57 47 53 51 75 65 72 74 53
Basic Earnings per Share		 $1.44 $1.53 $1.58 $1.57 $1.49 $1.42 $2.04 $1.99 $2.12 $2.35 $2.49
Weighted Average Basic Shares Outstanding		 146.43M 146.70M 146.91M 146.77M 147.08M 147.13M 146.96M 147.02M 146.86M 146.81M 146.72M
Diluted Earnings per Share		 $1.43 $1.53 $1.58 $1.55 $1.49 $1.42 $2.04 $1.97 $2.11 $2.34 $2.48
Weighted Average Diluted Shares Outstanding		 147.13M 147.41M 147.40M 147.46M 147.49M 147.55M 147.45M 147.55M 147.60M 147.48M 147.22M
Weighted Average Basic & Diluted Shares Outstanding		 146.48M 146.91M 146.93M 147.07M 147.09M 147.09M 146.91M 146.93M 146.80M 146.87M 146.63M
Cash Dividends to Common per Share		 $0.44 $0.44 $0.44 $0.44 $0.48 $0.48 $0.48 $0.48 $0.53 $0.53 $0.53

Annual Cash Flow Statements for ResMed

This table details how cash moves in and out of ResMed's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 6/30/2015 6/30/2016 6/30/2017 6/30/2018 6/30/2019 6/30/2020 6/30/2021 6/30/2022 6/30/2023 6/30/2024
Net Change in Cash & Equivalents		 -163 14 91 -633 -42 316 -168 -22 -46 10
Net Cash From Operating Activities		 409 548 414 505 459 802 737 351 693 1,401
Net Cash From Continuing Operating Activities		 409 548 414 505 459 802 737 351 693 1,401
Net Income / (Loss) Continuing Operations		 353 352 342 316 405 622 475 779 898 1,021
Consolidated Net Income / (Loss)		 353 352 342 316 405 622 475 779 898 1,021
Depreciation Expense		 73 87 112 120 151 155 157 160 165 177
Amortization Expense		 - - - 0.00 0.00 27 35 34 32 39
Non-Cash Adjustments To Reconcile Net Income		 48 50 39 60 81 97 69 86 60 119
Changes in Operating Assets and Liabilities, net		 -65 59 -80 9.47 -177 -98 1.41 -708 -462 45
Net Cash From Investing Activities		 -143 -1,126 -82 -102 -1,076 -180 -158 -230 -1,160 -270
Net Cash From Continuing Investing Activities		 -143 -1,126 -82 -102 -1,076 -180 -158 -230 -1,160 -270
Purchase of Property, Plant & Equipment		 -63 -59 -62 -63 -69 -95 -103 -135 -120 -99
Acquisitions		 -39 -1,051 -17 -9.78 -960 -39 -53 -64 -1,027 -149
Purchase of Investments		 -42 -8.97 -6.46 -29 -47 -32 -22 -21 -32 -13
Sale and/or Maturity of Investments		 - -7.10 3.32 - - -14 19 -10 19 -8.70
Net Cash From Financing Activities		 -256 613 -263 -1,027 581 -317 -765 -128 423 -1,119
Net Cash From Continuing Financing Activities		 -256 613 -263 -1,027 581 -317 -765 -128 423 -1,119
Repayment of Debt		 -182 -284 -545 -1,146 -712 -1,284 -612 -166 -405 -835
Repurchase of Common Equity		 -160 -102 - -54 -23 - - 0.00 0.00 -150
Payment of Dividends		 -158 -169 -198 -200 -213 -225 -230 -245 -261 -284
Issuance of Debt		 180 1,140 450 350 1,519 1,190 90 288 1,070 105
Issuance of Common Equity		 39 28 38 39 37 48 38 47 49 53
Other Financing Activities, net		 25 - -8.16 -15 -28 -46 -50 -52 -31 -8.76
Effect of Exchange Rate Changes		 -173 -21 21 -9.74 -5.56 11 18 -14 -2.15 -1.72
Cash Interest Paid		 - 11 28 28 36 40 24 22 47 46
Cash Income Taxes Paid		 49 69 93 171 243 180 221 478 217 278

Quarterly Cash Flow Statements for ResMed

This table details how cash moves in and out of ResMed's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025
Net Change in Cash & Equivalents		 -67 46 -25 -0.00 -19 1.15 28 0.45 188 96 411
Net Cash From Operating Activities		 45 129 283 237 286 273 402 440 326 309 579
Net Cash From Continuing Operating Activities		 45 129 283 237 286 273 402 440 326 309 579
Net Income / (Loss) Continuing Operations		 210 225 233 230 219 209 300 292 311 345 365
Consolidated Net Income / (Loss)		 210 225 233 230 219 209 300 292 311 345 365
Depreciation Expense		 36 38 44 47 45 45 43 44 45 46 44
Amortization Expense		 7.76 7.77 8.43 8.44 8.51 8.59 11 11 8.98 9.46 8.24
Non-Cash Adjustments To Reconcile Net Income		 22 11 12 16 23 54 6.08 36 20 23 29
Changes in Operating Assets and Liabilities, net		 -232 -153 -14 -63 -9.59 -44 41 57 -59 -115 132
Net Cash From Investing Activities		 -59 -1,026 -28 -47 -149 -41 -33 -47 2.15 -37 -32
Net Cash From Continuing Investing Activities		 -59 -1,026 -28 -47 -149 -41 -33 -47 2.15 -37 -32
Purchase of Property, Plant & Equipment		 -29 -27 -29 -34 -30 -23 -21 -25 -18 -21 -21
Acquisitions		 -22 -996 -2.41 -5.81 -114 -8.71 -5.00 -21 -1.77 -3.50 -2.99
Purchase of Investments		 -4.29 -13 -13 -2.50 -3.68 -3.63 -2.39 -3.07 18 -20 -2.05
Sale and/or Maturity of Investments		 -3.04 10 16 -3.77 -1.25 -5.46 -4.58 2.58 4.13 7.42 -5.95
Net Cash From Financing Activities		 -42 933 -280 -189 -151 -239 -336 -393 -151 -148 -144
Net Cash From Continuing Financing Activities		 -42 933 -280 -189 -151 -239 -336 -393 -151 -148 -144
Repurchase of Common Equity		 - - - - 0.00 -50 -50 -50 -50 -75 -75
Payment of Dividends		 -64 -65 -65 -67 -72 -71 -70 -72 -79 -78 -78
Issuance of Common Equity		 2.61 22 0.98 23 0.98 20 4.89 28 8.38 27 9.02
Other Financing Activities, net		 -0.06 -30 -0.90 -0.02 -0.23 -7.80 -0.31 0.87 -0.39 -17 -0.36
Effect of Exchange Rate Changes		 -11 11 -0.21 -2.33 -4.96 8.42 -5.30 0.13 11 -29 7.96
Cash Interest Paid		 7.13 10 15 15 15 14 11 5.92 7.35 -0.07 14
Cash Income Taxes Paid		 53 55 38 71 77 97 62 43 106 119 -27

Annual Balance Sheets for ResMed

This table presents ResMed's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 6/30/2015 6/30/2016 6/30/2017 6/30/2018 6/30/2019 6/30/2020 6/30/2021 6/30/2022 6/30/2023 6/30/2024
Total Assets		 2,182 3,257 3,468 3,064 4,108 4,587 4,728 5,096 6,752 6,872
Total Current Assets		 1,408 1,420 1,644 1,066 1,145 1,523 1,575 1,931 2,368 2,358
Cash & Equivalents		 717 731 822 189 147 463 295 274 228 238
Accounts Receivable		 363 382 451 484 528 475 614 576 705 837
Inventories, net		 247 224 268 269 350 417 457 744 998 822
Prepaid Expenses		 81 82 103 125 120 75 208 338 437 460
Plant, Property, & Equipment, net		 388 384 394 387 387 417 463 498 538 548
Total Noncurrent Assets		 386 1,453 1,430 1,612 2,575 2,647 2,690 2,666 3,846 3,967
Goodwill		 264 1,059 1,065 1,069 1,856 1,890 1,928 1,936 2,770 2,842
Intangible Assets		 47 300 262 215 522 448 393 346 552 486
Noncurrent Deferred & Refundable Income Taxes		 46 55 62 54 45 41 80 80 133 204
Other Noncurrent Operating Assets		 28 38 42 274 151 267 289 304 390 435
Total Liabilities & Shareholders' Equity		 2,182 3,257 3,468 3,064 4,108 4,587 4,728 5,096 6,752 6,872
Total Liabilities		 594 1,562 1,508 1,005 2,035 2,090 1,842 1,735 2,622 2,008
Total Current Liabilities		 266 638 360 511 556 603 912 689 759 911
Short-Term Debt		 - 299 - 11 12 12 12 9.92 9.90 9.90
Accounts Payable		 81 93 93 93 116 136 138 159 151 238
Accrued Expenses		 133 157 186 186 266 270 321 345 366 378
Current Deferred Revenue		 36 50 52 61 89 99 110 109 138 153
Current Deferred & Payable Income Tax Liabilities		 16 39 29 160 73 65 308 45 72 108
Other Current Liabilities		 - - - - 0.00 21 24 22 22 25
Total Noncurrent Liabilities		 328 924 1,148 494 1,479 1,488 931 1,046 1,863 1,098
Long-Term Debt		 301 873 1,079 270 1,259 1,164 643 765 1,431 697
Noncurrent Deferred Revenue		 21 40 53 210 207 200 154 144 156 137
Noncurrent Deferred & Payable Income Tax Liabilities		 6.37 9.06 14 13 11 13 11 9.71 91 79
Other Noncurrent Operating Liabilities		 0.00 1.21 2.43 0.92 2.06 110 122 126 185 184
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 1,587 1,695 1,960 2,059 2,072 2,497 2,886 3,361 4,130 4,864
Total Preferred & Common Equity		 1,587 1,695 1,960 2,059 2,072 2,497 2,886 3,361 4,130 4,864
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 1,587 1,695 1,960 2,059 2,072 2,497 2,886 3,361 4,130 4,864
Common Stock		 1,229 1,304 1,380 1,451 1,512 1,571 1,623 1,683 1,773 1,897
Retained Earnings		 1,976 2,160 2,316 2,432 2,436 2,833 3,080 3,614 4,253 4,992
Treasury Stock		 -1,445 -1,547 -1,547 -1,600 -1,623 -1,623 -1,623 -1,623 -1,623 -1,773
Accumulated Other Comprehensive Income / (Loss)		 -174 -223 -189 -224 -253 -284 -193 -313 -273 -252

Quarterly Balance Sheets for ResMed

This table presents ResMed's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025
Total Assets		 5,178 6,676 6,714 6,752 6,741 6,905 6,815 6,872 7,222 7,141 7,567
Total Current Assets		 2,034 2,325 2,338 2,368 2,305 2,378 2,351 2,358 2,641 2,836 3,208
Cash & Equivalents		 207 253 228 228 209 210 238 238 426 522 933
Accounts Receivable		 620 672 686 705 692 730 779 837 811 860 908
Inventories, net		 865 989 1,011 998 958 933 829 822 918 882 863
Prepaid Expenses		 341 411 412 437 445 505 505 460 486 572 505
Plant, Property, & Equipment, net		 487 523 529 538 534 552 540 548 560 520 535
Total Noncurrent Assets		 2,656 3,828 3,847 3,846 3,902 3,975 3,924 3,967 4,021 3,785 3,823
Goodwill		 1,939 2,767 2,784 2,770 2,812 2,862 2,836 2,842 2,886 2,805 2,849
Intangible Assets		 338 587 570 552 563 528 501 486 479 438 430
Noncurrent Deferred & Refundable Income Taxes		 81 86 96 133 138 156 162 204 221 209 217
Other Noncurrent Operating Assets		 299 388 398 390 389 429 424 435 436 332 327
Total Liabilities & Shareholders' Equity		 5,178 6,676 6,714 6,752 6,741 6,905 6,815 6,872 7,222 7,141 7,567
Total Liabilities		 1,745 2,938 2,781 2,622 2,490 2,423 2,185 2,008 2,027 1,888 2,021
Total Current Liabilities		 693 733 762 759 771 764 773 911 904 852 941
Short-Term Debt		 9.91 9.90 9.90 9.90 9.91 9.90 9.90 9.90 9.90 9.91 9.91
Accounts Payable		 181 196 162 151 177 202 177 238 249 220 223
Accrued Expenses		 324 312 347 366 348 332 356 378 366 353 386
Current Deferred Revenue		 108 134 141 138 147 149 151 153 157 157 160
Current Deferred & Payable Income Tax Liabilities		 48 58 78 72 67 47 55 108 94 85 133
Other Current Liabilities		 21 22 23 22 22 24 24 25 28 28 29
Total Noncurrent Liabilities		 1,052 2,205 2,020 1,863 1,720 1,659 1,412 1,098 1,123 1,036 1,080
Long-Term Debt		 785 1,791 1,576 1,431 1,352 1,217 997 697 668 663 663
Noncurrent Deferred Revenue		 135 140 146 156 134 140 144 137 144 147 151
Noncurrent Deferred & Payable Income Tax Liabilities		 12 108 113 91 88 89 87 79 84 77 79
Other Noncurrent Operating Liabilities		 120 167 185 185 147 214 184 184 228 150 187
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 3,433 3,738 3,933 4,130 4,250 4,482 4,630 4,864 5,195 5,253 5,546
Total Preferred & Common Equity		 3,433 3,738 3,933 4,130 4,250 4,482 4,630 4,864 5,195 5,253 5,546
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 3,433 3,738 3,933 4,130 4,250 4,482 4,630 4,864 5,195 5,253 5,546
Common Stock		 1,702 1,711 1,730 1,773 1,792 1,824 1,849 1,897 1,925 1,958 1,991
Retained Earnings		 3,760 3,920 4,088 4,253 4,402 4,540 4,770 4,992 5,225 5,492 5,779
Treasury Stock		 -1,623 -1,623 -1,623 -1,623 -1,623 -1,673 -1,723 -1,773 -1,823 -1,898 -1,973
Accumulated Other Comprehensive Income / (Loss)		 -406 -270 -262 -273 -320 -208 -265 -252 -132 -299 -251

Annual Metrics And Ratios for ResMed

This table displays calculated financial ratios and metrics derived from ResMed's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 6/30/2015 6/30/2016 6/30/2017 6/30/2018 6/30/2019 6/30/2020 6/30/2021 6/30/2022 6/30/2023 6/30/2024
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 7.97% 9.52% 12.40% 13.23% 11.38% 13.44% 8.11% 11.93% 18.02% 10.95%
EBITDA Growth		 1.90% 6.59% 4.09% 20.51% 10.12% 36.08% 13.40% 6.77% 14.24% 12.90%
EBIT Growth		 2.34% 4.43% -0.93% 24.05% 6.61% 40.27% 15.17% 7.92% 16.65% 13.50%
NOPAT Growth		 2.11% 3.81% 1.21% -5.76% 37.71% 52.00% -29.33% 67.28% 13.60% 15.53%
Net Income Growth		 2.20% -0.14% -2.87% -7.80% 28.20% 53.65% -23.67% 64.26% 15.15% 13.75%
EPS Growth		 3.35% 0.81% -3.61% -8.75% 27.85% 52.50% -24.12% 63.58% 14.91% 13.63%
Operating Cash Flow Growth		 0.31% 34.02% -24.43% 21.97% -9.10% 74.76% -8.17% -52.34% 97.44% 102.11%
Free Cash Flow Firm Growth		 52.10% -298.00% 143.00% 47.12% -250.67% 213.51% -33.16% -56.57% -386.21% 292.53%
Invested Capital Growth		 1.50% 82.48% 3.78% -2.94% 48.53% 0.44% 1.11% 19.00% 38.34% -0.19%
Revenue Q/Q Growth		 2.31% 3.70% 1.88% 2.94% 3.22% 2.26% 3.42% 1.09% 5.16% 2.21%
EBITDA Q/Q Growth		 -0.68% 6.03% 1.17% 3.54% -2.48% 15.99% 1.74% -0.02% 4.47% 4.68%
EBIT Q/Q Growth		 -0.30% 4.92% 1.21% 3.65% -4.89% 16.43% 2.09% 0.04% 4.31% 5.53%
NOPAT Q/Q Growth		 0.76% 0.25% 6.84% 2.56% -5.51% 16.76% 2.68% 1.51% 2.15% 8.42%
Net Income Q/Q Growth		 -0.08% -1.22% 5.71% 2.67% -9.20% 21.27% 3.78% -0.01% 4.01% 6.53%
EPS Q/Q Growth		 0.41% -0.80% 4.80% 2.82% -9.09% 20.96% 3.51% -0.19% 3.92% 6.46%
Operating Cash Flow Q/Q Growth		 -3.90% 8.43% -1.48% -2.11% 2.78% 30.70% -12.34% -29.51% 29.50% 16.91%
Free Cash Flow Firm Q/Q Growth		 -9.37% -848.63% 155.72% 14.60% -5.84% 29.79% -17.27% -22.41% 11.31% 23.04%
Invested Capital Q/Q Growth		 3.55% 53.62% 0.95% -0.96% -0.45% -2.15% 1.13% 2.78% 1.00% -1.22%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 60.24% 58.00% 58.15% 57.04% 57.32% 58.09% 57.53% 56.57% 55.78% 56.67%
EBITDA Margin		 29.10% 28.32% 26.23% 27.91% 27.60% 33.10% 34.72% 33.12% 32.06% 32.62%
Operating Margin		 24.38% 23.33% 20.60% 23.15% 22.22% 27.38% 28.27% 27.96% 26.80% 28.17%
EBIT Margin		 24.75% 23.60% 20.80% 22.79% 21.81% 26.97% 28.73% 27.70% 27.38% 28.01%
Profit (Net Income) Margin		 21.02% 19.17% 16.56% 13.49% 15.52% 21.02% 14.84% 21.78% 21.25% 21.79%
Tax Burden Percent		 80.95% 80.17% 81.74% 60.54% 77.98% 84.80% 53.70% 81.15% 81.47% 80.72%
Interest Burden Percent		 104.92% 101.30% 97.41% 97.75% 91.26% 91.92% 96.21% 96.89% 95.27% 96.38%
Effective Tax Rate		 19.05% 19.83% 18.26% 39.46% 22.02% 15.20% 46.30% 18.85% 18.53% 19.28%
Return on Invested Capital (ROIC)		 28.51% 20.80% 15.99% 15.02% 16.89% 21.44% 15.03% 22.84% 20.04% 19.96%
ROIC Less NNEP Spread (ROIC-NNEP)		 24.28% 89.76% 14.34% 7.91% 9.15% 14.37% 13.03% 15.34% 17.16% 14.67%
Return on Net Nonoperating Assets (RNNOA)		 -7.41% 0.67% 2.74% 0.69% 2.69% 5.77% 2.60% 2.12% 3.93% 2.74%
Return on Equity (ROE)		 21.10% 21.47% 18.73% 15.70% 19.59% 27.21% 17.63% 24.96% 23.96% 22.70%
Cash Return on Invested Capital (CROIC)		 27.02% -37.60% 12.28% 18.00% -22.16% 21.00% 13.93% 5.49% -12.14% 20.15%
Operating Return on Assets (OROA)		 18.29% 15.96% 12.78% 16.33% 15.86% 18.34% 19.72% 20.18% 19.52% 19.27%
Return on Assets (ROA)		 15.54% 12.96% 10.18% 9.66% 11.28% 14.30% 10.19% 15.87% 15.15% 14.99%
Return on Common Equity (ROCE)		 21.10% 21.47% 18.73% 15.70% 19.59% 27.21% 17.63% 24.96% 23.96% 22.70%
Return on Equity Simple (ROE_SIMPLE)		 22.23% 20.79% 17.46% 15.33% 19.52% 24.90% 16.44% 23.19% 21.73% 20.99%
Net Operating Profit after Tax (NOPAT)		 331 344 348 328 452 687 485 812 922 1,065
NOPAT Margin		 19.73% 18.70% 16.84% 14.02% 17.33% 23.22% 15.18% 22.69% 21.84% 22.74%
Net Nonoperating Expense Percent (NNEP)		 4.23% -68.96% 1.65% 7.11% 7.75% 7.07% 2.00% 7.50% 2.87% 5.29%
Cost of Revenue to Revenue		 39.76% 42.00% 41.85% 42.96% 42.68% 41.91% 42.47% 43.43% 44.22% 43.33%
SG&A Expenses to Revenue		 28.51% 26.54% 26.80% 25.65% 24.75% 22.88% 20.97% 20.61% 20.70% 19.57%
R&D to Revenue		 6.84% 6.45% 6.99% 6.63% 6.93% 6.83% 7.05% 7.09% 6.81% 6.56%
Operating Expenses to Revenue		 35.87% 34.67% 37.54% 33.89% 35.10% 30.71% 29.26% 28.62% 28.98% 28.50%
Earnings before Interest and Taxes (EBIT)		 415 434 430 533 569 798 918 991 1,156 1,312
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 489 521 542 653 719 979 1,110 1,185 1,354 1,529
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 4.45 4.76 5.22 6.76 8.07 10.73 12.09 8.94 7.67 5.77
Price to Tangible Book Value (P/TBV)		 5.54 24.01 16.15 17.97 0.00 169.08 61.73 27.85 39.26 18.26
Price to Revenue (P/Rev)		 4.21 4.39 4.95 5.95 6.41 9.06 10.91 8.39 7.50 5.99
Price to Earnings (P/E)		 20.02 22.88 29.90 44.12 41.31 43.12 73.53 38.54 35.31 27.48
Dividend Yield		 2.23% 2.09% 2.25% 1.44% 1.27% 0.84% 0.65% 0.82% 0.82% 1.01%
Earnings Yield		 5.00% 4.37% 3.34% 2.27% 2.42% 2.32% 1.36% 2.60% 2.83% 3.64%
Enterprise Value to Invested Capital (EV/IC)		 5.68 3.98 4.73 6.51 5.58 8.57 10.86 7.91 6.16 5.35
Enterprise Value to Revenue (EV/Rev)		 3.96 4.63 5.08 5.99 6.84 9.31 11.03 8.53 7.79 6.09
Enterprise Value to EBITDA (EV/EBITDA)		 13.61 16.33 19.35 21.46 24.80 28.11 31.76 25.77 24.30 18.66
Enterprise Value to EBIT (EV/EBIT)		 16.00 19.60 24.40 26.29 31.38 34.51 38.38 30.81 28.46 21.73
Enterprise Value to NOPAT (EV/NOPAT)		 20.07 24.73 30.14 42.74 39.49 40.08 72.65 37.62 35.68 26.77
Enterprise Value to Operating Cash Flow (EV/OCF)		 16.26 15.52 25.33 27.76 38.86 34.30 47.85 86.97 47.46 20.36
Enterprise Value to Free Cash Flow (EV/FCFF)		 21.17 0.00 39.25 35.65 0.00 40.92 78.43 156.44 0.00 26.52
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.19 0.69 0.55 0.14 0.61 0.47 0.23 0.23 0.35 0.15
Long-Term Debt to Equity		 0.19 0.52 0.55 0.13 0.61 0.47 0.22 0.23 0.35 0.14
Financial Leverage		 -0.31 0.01 0.19 0.09 0.29 0.40 0.20 0.14 0.23 0.19
Leverage Ratio		 1.36 1.66 1.84 1.63 1.74 1.90 1.73 1.57 1.58 1.51
Compound Leverage Factor		 1.42 1.68 1.79 1.59 1.58 1.75 1.67 1.52 1.51 1.46
Debt to Total Capital		 15.92% 40.90% 35.49% 12.03% 38.01% 32.02% 18.51% 18.74% 25.87% 12.69%
Short-Term Debt to Total Capital		 0.00% 10.44% 0.00% 0.49% 0.36% 0.33% 0.34% 0.24% 0.18% 0.18%
Long-Term Debt to Total Capital		 15.92% 30.46% 35.49% 11.54% 37.66% 31.69% 18.17% 18.50% 25.69% 12.52%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 84.08% 59.10% 64.51% 87.97% 61.99% 67.98% 81.49% 81.26% 74.13% 87.31%
Debt to EBITDA		 0.62 2.25 1.99 0.43 1.77 1.20 0.59 0.65 1.06 0.46
Net Debt to EBITDA		 -0.85 0.85 0.47 0.14 1.56 0.73 0.32 0.42 0.90 0.31
Long-Term Debt to EBITDA		 0.62 1.68 1.99 0.41 1.75 1.19 0.58 0.65 1.06 0.46
Debt to NOPAT		 0.91 3.41 3.10 0.86 2.81 1.71 1.35 0.96 1.56 0.66
Net Debt to NOPAT		 -1.26 1.28 0.74 0.28 2.49 1.04 0.74 0.62 1.32 0.44
Long-Term Debt to NOPAT		 0.91 2.54 3.10 0.82 2.79 1.70 1.33 0.94 1.55 0.65
Altman Z-Score		 10.42 5.32 6.45 10.98 7.02 10.02 13.76 13.02 9.61 10.96
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 5.28 2.23 4.57 2.08 2.06 2.53 1.73 2.80 3.12 2.59
Quick Ratio		 4.05 1.75 3.53 1.32 1.22 1.56 1.00 1.23 1.23 1.18
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 314 -622 267 393 -592 673 449 195 -559 1,076
Operating Cash Flow to CapEx		 654.14% 936.09% 665.48% 807.00% 668.10% 841.56% 717.27% 260.43% 579.33% 1,408.87%
Free Cash Flow to Firm to Interest Expense		 54.33 -55.47 9.47 13.87 -16.39 17.09 19.02 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 70.76 48.90 14.66 17.81 12.70 20.38 31.18 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 59.94 43.67 12.46 15.60 10.80 17.96 26.83 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.74 0.68 0.61 0.72 0.73 0.68 0.69 0.73 0.71 0.69
Accounts Receivable Turnover		 4.65 4.94 4.96 5.01 5.15 5.90 5.87 6.01 6.59 6.08
Inventory Turnover		 3.24 3.28 3.51 3.74 3.60 3.23 3.11 2.59 2.14 2.23
Fixed Asset Turnover		 4.08 4.76 5.31 5.99 6.74 7.35 7.26 7.44 8.15 8.63
Accounts Payable Turnover		 8.02 8.89 9.33 10.84 10.67 9.85 9.92 10.45 12.05 10.45
Days Sales Outstanding (DSO)		 78.50 73.91 73.52 72.85 70.87 61.91 62.17 60.71 55.35 60.07
Days Inventory Outstanding (DIO)		 112.72 111.39 103.97 97.49 101.44 112.89 117.47 141.05 170.24 163.64
Days Payable Outstanding (DPO)		 45.53 41.05 39.10 33.67 34.19 37.04 36.80 34.91 30.30 34.93
Cash Conversion Cycle (CCC)		 145.69 144.25 138.39 136.67 138.11 137.76 142.84 166.85 195.30 188.79
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 1,171 2,136 2,217 2,152 3,196 3,210 3,246 3,862 5,343 5,333
Invested Capital Turnover		 1.44 1.11 0.95 1.07 0.97 0.92 0.99 1.01 0.92 0.88
Increase / (Decrease) in Invested Capital		 17 966 81 -65 1,044 14 36 617 1,481 -10
Enterprise Value (EV)		 6,647 8,505 10,490 14,018 17,839 27,518 35,252 30,537 32,904 28,523
Market Capitalization		 7,064 8,063 10,233 13,925 16,715 26,805 34,892 30,036 31,691 28,054
Book Value per Share		 $11.26 $12.07 $13.82 $14.42 $14.45 $17.26 $19.83 $22.97 $28.11 $33.11
Tangible Book Value per Share		 $9.05 $2.39 $4.47 $5.43 ($2.14) $1.10 $3.88 $7.37 $5.49 $10.46
Total Capital		 1,888 2,868 3,039 2,340 3,343 3,673 3,541 4,136 5,571 5,571
Total Debt		 301 1,173 1,079 281 1,271 1,176 655 775 1,441 707
Total Long-Term Debt		 301 873 1,079 270 1,259 1,164 643 765 1,431 697
Net Debt		 -417 441 257 93 1,124 713 360 502 1,213 469
Capital Expenditures (CapEx)		 63 59 62 63 69 95 103 135 120 99
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 424 350 462 377 454 470 380 978 1,391 1,219
Debt-free Net Working Capital (DFNWC)		 1,141 1,081 1,284 566 601 933 675 1,252 1,619 1,457
Net Working Capital (NWC)		 1,141 782 1,284 554 589 921 663 1,242 1,609 1,447
Net Nonoperating Expense (NNE)		 -22 -8.51 5.77 12 47 65 11 32 25 44
Net Nonoperating Obligations (NNO)		 -417 441 257 93 1,124 713 360 502 1,213 469
Total Depreciation and Amortization (D&A)		 73 87 112 120 151 181 192 194 198 216
Debt-free, Cash-free Net Working Capital to Revenue		 25.26% 19.02% 22.35% 16.12% 17.43% 15.88% 11.88% 27.34% 32.95% 26.01%
Debt-free Net Working Capital to Revenue		 67.98% 58.80% 62.12% 24.18% 23.07% 31.54% 21.11% 34.99% 38.34% 31.10%
Net Working Capital to Revenue		 67.98% 42.52% 62.12% 23.69% 22.61% 31.14% 20.74% 34.72% 38.11% 30.89%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 $2.51 $2.51 $2.42 $2.21 $2.83 $4.31 $3.27 $5.34 $6.12 $6.94
Adjusted Weighted Average Basic Shares Outstanding		 140.47M 140.24M 141.36M 142.76M 143.11M 144.34M 145.31M 146.07M 146.77M 147.02M
Adjusted Diluted Earnings per Share		 $2.47 $2.49 $2.40 $2.19 $2.80 $4.27 $3.24 $5.30 $6.09 $6.92
Adjusted Weighted Average Diluted Shares Outstanding		 142.69M 141.67M 142.45M 143.99M 144.48M 145.65M 146.45M 147.04M 147.46M 147.55M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 140.52M 140.70M 142.21M 142.68M 143.67M 144.90M 145.68K 146.42M 147.07M 146.93M
Normalized Net Operating Profit after Tax (NOPAT)		 331 349 373 339 491 686 490 813 939 1,117
Normalized NOPAT Margin		 19.73% 19.00% 18.06% 14.49% 18.84% 23.20% 15.32% 22.73% 22.23% 23.85%
Pre Tax Income Margin		 25.96% 23.91% 20.26% 22.28% 19.91% 24.79% 27.64% 26.84% 26.09% 27.00%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 71.91 38.72 15.23 18.81 15.72 20.26 38.87 0.00 0.00 0.00
NOPAT to Interest Expense		 57.34 30.69 12.33 11.57 12.49 17.45 20.54 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 61.09 33.50 13.02 16.60 13.82 17.84 34.53 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 46.52 25.47 10.12 9.36 10.59 15.02 16.19 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 44.69% 48.06% 57.85% 63.37% 52.55% 36.26% 48.52% 31.48% 29.04% 27.78%
Augmented Payout Ratio		 90.12% 77.02% 57.85% 80.42% 58.20% 36.26% 48.52% 31.48% 29.04% 42.47%

Quarterly Metrics And Ratios for ResMed

This table displays calculated financial ratios and metrics derived from ResMed's official financial filings.

Metric Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 5.12% 15.52% 29.20% 22.66% 16.00% 12.48% 7.17% 9.01% 11.08% 10.26% 7.92%
EBITDA Growth		 0.59% 12.77% 24.93% 19.91% 9.36% -1.96% 23.32% 19.58% 27.12% 45.42% 6.32%
EBIT Growth		 2.04% 17.01% 29.91% 19.41% 7.41% -5.00% 26.76% 23.41% 32.01% 53.39% 7.92%
NOPAT Growth		 7.58% 8.89% 30.37% 9.15% 5.09% -3.85% 24.11% 36.36% 34.98% 55.26% 24.25%
Net Income Growth		 3.37% 11.48% 29.88% 17.74% 4.25% -7.16% 29.24% 27.25% 41.90% 65.05% 21.48%
EPS Growth		 2.88% 11.68% 29.51% 17.42% 4.20% -7.19% 29.11% 27.10% 41.61% 64.79% 21.57%
Operating Cash Flow Growth		 168.02% -41.50% 140.61% 198.71% 541.00% 112.10% 42.28% 85.36% 13.71% 13.12% 43.93%
Free Cash Flow Firm Growth		 -584.33% -9,614.35% -255.89% -207.51% -371.13% 100.61% 114.82% 125.68% 123.59% 4,977.63% 153.50%
Invested Capital Growth		 13.09% 45.55% 40.79% 38.34% 34.36% 4.03% 2.05% -0.19% 0.80% -1.72% -2.08%
Revenue Q/Q Growth		 3.89% 8.78% 8.04% 0.46% -1.76% 5.49% 2.94% 2.19% 0.11% 4.70% 0.75%
EBITDA Q/Q Growth		 8.17% 5.53% 7.50% -2.28% -1.34% -5.40% 35.21% -5.24% 4.88% 8.22% -1.15%
EBIT Q/Q Growth		 10.06% 5.87% 6.16% -3.47% -1.00% -6.36% 41.64% -6.02% 5.90% 8.80% -0.35%
NOPAT Q/Q Growth		 5.95% 3.86% 4.91% -5.46% 2.01% -4.97% 35.43% 3.87% 0.97% 9.31% 8.38%
Net Income Q/Q Growth		 7.90% 6.86% 3.37% -1.22% -4.46% -4.84% 43.91% -2.75% 6.54% 10.68% 5.93%
EPS Q/Q Growth		 8.33% 6.99% 3.27% -1.90% -3.87% -4.70% 43.66% -3.43% 7.11% 10.90% 5.98%
Operating Cash Flow Q/Q Growth		 -43.81% 188.02% 119.66% -15.97% 20.57% -4.70% 47.35% 9.47% -26.03% -5.20% 87.50%
Free Cash Flow Firm Q/Q Growth		 40.14% -484.03% 9.32% 3.00% 8.29% 100.75% 2,117.28% 68.12% -15.75% 61.69% 10.70%
Invested Capital Q/Q Growth		 4.11% 31.45% 0.09% 1.00% 1.11% 1.77% -1.81% -1.22% 2.12% -0.78% -2.17%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 56.91% 56.08% 55.31% 55.02% 54.44% 55.64% 57.88% 58.50% 58.57% 58.60% 59.33%
EBITDA Margin		 33.15% 32.15% 31.99% 31.12% 31.25% 28.03% 36.81% 34.14% 35.76% 36.96% 36.27%
Operating Margin		 29.02% 27.10% 26.92% 24.53% 26.22% 23.66% 31.29% 31.17% 31.63% 32.54% 33.00%
EBIT Margin		 28.51% 27.75% 27.27% 26.20% 26.40% 23.44% 32.25% 29.66% 31.38% 32.60% 32.25%
Profit (Net Income) Margin		 22.15% 21.76% 20.82% 20.47% 19.91% 17.96% 25.10% 23.89% 25.43% 26.88% 28.26%
Tax Burden Percent		 80.40% 82.18% 80.34% 82.97% 80.61% 80.48% 80.04% 81.69% 81.19% 82.38% 87.39%
Interest Burden Percent		 96.62% 95.41% 95.03% 94.16% 93.52% 95.21% 97.26% 98.61% 99.82% 100.07% 100.27%
Effective Tax Rate		 19.60% 17.82% 19.66% 17.03% 19.39% 19.52% 19.96% 18.31% 18.81% 17.62% 12.61%
Return on Invested Capital (ROIC)		 22.32% 18.80% 19.20% 18.68% 19.62% 15.90% 21.48% 22.35% 22.76% 24.23% 27.11%
ROIC Less NNEP Spread (ROIC-NNEP)		 20.31% 18.28% 18.21% 18.82% 18.07% 14.92% 21.55% 20.07% 22.32% 24.38% 24.16%
Return on Net Nonoperating Assets (RNNOA)		 3.52% 5.40% 4.64% 4.31% 4.09% 4.65% 5.35% 3.75% 3.32% 2.92% 1.21%
Return on Equity (ROE)		 25.83% 24.20% 23.84% 22.98% 23.72% 20.56% 26.84% 26.10% 26.08% 27.16% 28.32%
Cash Return on Invested Capital (CROIC)		 9.56% -18.12% -13.92% -12.14% -9.51% 13.20% 16.36% 20.15% 20.34% 25.02% 27.23%
Operating Return on Assets (OROA)		 20.86% 18.30% 18.85% 18.68% 19.38% 15.55% 21.86% 20.40% 21.60% 22.87% 22.52%
Return on Assets (ROA)		 16.21% 14.35% 14.39% 14.59% 14.61% 11.91% 17.01% 16.43% 17.51% 18.86% 19.73%
Return on Common Equity (ROCE)		 25.83% 24.20% 23.84% 22.98% 23.72% 20.56% 26.84% 26.10% 26.08% 27.16% 28.32%
Return on Equity Simple (ROE_SIMPLE)		 22.91% 21.65% 21.94% 0.00% 21.33% 19.87% 20.70% 0.00% 21.42% 23.77% 23.68%
Net Operating Profit after Tax (NOPAT)		 222 230 242 228 233 221 300 311 314 344 373
NOPAT Margin		 23.33% 22.27% 21.63% 20.35% 21.13% 19.04% 25.05% 25.46% 25.68% 26.81% 28.84%
Net Nonoperating Expense Percent (NNEP)		 2.01% 0.53% 0.99% -0.15% 1.56% 0.98% -0.06% 2.28% 0.44% -0.15% 2.94%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - 3.88% - - - 5.80% 5.99%
Cost of Revenue to Revenue		 43.09% 43.92% 44.69% 44.98% 45.56% 44.36% 42.12% 41.50% 41.43% 41.40% 40.67%
SG&A Expenses to Revenue		 20.41% 20.48% 20.45% 21.38% 20.22% 19.11% 19.21% 19.80% 19.52% 18.85% 18.99%
R&D to Revenue		 6.65% 6.76% 6.84% 6.96% 6.87% 6.35% 6.44% 6.61% 6.49% 6.35% 6.50%
Operating Expenses to Revenue		 27.89% 28.97% 28.39% 30.49% 28.22% 31.98% 26.58% 27.33% 26.94% 26.05% 26.33%
Earnings before Interest and Taxes (EBIT)		 271 287 305 294 291 273 386 363 384 418 417
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 315 332 357 349 344 326 441 418 438 474 468
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 9.14 8.02 8.06 7.67 5.06 5.59 6.26 5.77 6.90 6.39 5.93
Price to Tangible Book Value (P/TBV)		 27.14 78.05 54.73 39.26 24.60 22.96 22.43 18.26 19.60 16.70 14.50
Price to Revenue (P/Rev)		 8.65 7.97 7.89 7.50 4.92 5.57 6.32 5.99 7.46 6.81 6.55
Price to Earnings (P/E)		 39.89 37.04 36.73 35.31 23.74 28.15 30.25 27.48 32.23 26.88 25.03
Dividend Yield		 0.79% 0.84% 0.81% 0.82% 1.23% 1.08% 0.95% 1.01% 0.81% 0.88% 0.92%
Earnings Yield		 2.51% 2.70% 2.72% 2.83% 4.21% 3.55% 3.31% 3.64% 3.10% 3.72% 3.99%
Enterprise Value to Invested Capital (EV/IC)		 7.95 5.96 6.25 6.16 4.20 4.74 5.51 5.35 6.63 6.24 6.17
Enterprise Value to Revenue (EV/Rev)		 8.82 8.38 8.23 7.79 5.18 5.79 6.49 6.09 7.51 6.84 6.50
Enterprise Value to EBITDA (EV/EBITDA)		 26.92 25.74 25.51 24.30 16.39 18.95 20.38 18.66 22.27 19.05 18.14
Enterprise Value to EBIT (EV/EBIT)		 32.06 30.36 29.82 28.46 19.28 22.45 23.93 21.73 25.70 21.74 20.62
Enterprise Value to NOPAT (EV/NOPAT)		 38.61 37.25 36.62 35.68 24.29 28.21 30.29 26.77 31.49 26.57 24.30
Enterprise Value to Operating Cash Flow (EV/OCF)		 69.25 85.16 61.75 47.46 24.25 24.17 24.83 20.36 25.07 22.84 19.73
Enterprise Value to Free Cash Flow (EV/FCFF)		 88.24 0.00 0.00 0.00 0.00 36.64 34.04 26.52 32.73 24.73 22.42
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.23 0.48 0.40 0.35 0.32 0.27 0.22 0.15 0.13 0.13 0.12
Long-Term Debt to Equity		 0.23 0.48 0.40 0.35 0.32 0.27 0.22 0.14 0.13 0.13 0.12
Financial Leverage		 0.17 0.30 0.25 0.23 0.23 0.31 0.25 0.19 0.15 0.12 0.05
Leverage Ratio		 1.53 1.66 1.61 1.58 1.55 1.65 1.58 1.51 1.48 1.44 1.41
Compound Leverage Factor		 1.48 1.58 1.53 1.49 1.45 1.57 1.54 1.49 1.48 1.44 1.42
Debt to Total Capital		 18.81% 32.51% 28.74% 25.87% 24.26% 21.49% 17.86% 12.69% 11.54% 11.35% 10.82%
Short-Term Debt to Total Capital		 0.23% 0.18% 0.18% 0.18% 0.18% 0.17% 0.18% 0.18% 0.17% 0.17% 0.16%
Long-Term Debt to Total Capital		 18.58% 32.33% 28.56% 25.69% 24.08% 21.32% 17.69% 12.52% 11.37% 11.19% 10.66%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 81.19% 67.49% 71.26% 74.13% 75.74% 78.51% 82.14% 87.31% 88.46% 88.65% 89.18%
Debt to EBITDA		 0.67 1.47 1.22 1.06 0.98 0.89 0.69 0.46 0.42 0.38 0.37
Net Debt to EBITDA		 0.50 1.26 1.05 0.90 0.83 0.74 0.53 0.31 0.15 0.09 -0.14
Long-Term Debt to EBITDA		 0.66 1.46 1.22 1.06 0.98 0.88 0.68 0.46 0.41 0.37 0.37
Debt to NOPAT		 0.96 2.13 1.76 1.56 1.46 1.33 1.02 0.66 0.59 0.53 0.50
Net Debt to NOPAT		 0.71 1.83 1.50 1.32 1.23 1.10 0.78 0.44 0.22 0.12 -0.19
Long-Term Debt to NOPAT		 0.95 2.12 1.75 1.55 1.45 1.32 1.01 0.65 0.58 0.52 0.49
Altman Z-Score		 12.99 7.94 8.72 9.19 7.16 8.19 10.08 10.51 12.76 12.96 12.04
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 2.94 3.17 3.07 3.12 2.99 3.11 3.04 2.59 2.92 3.33 3.41
Quick Ratio		 1.19 1.26 1.20 1.23 1.17 1.23 1.32 1.18 1.37 1.62 1.96
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -244 -1,424 -1,291 -1,252 -1,149 8.63 191 322 271 438 485
Operating Cash Flow to CapEx		 153.71% 470.33% 980.55% 689.24% 953.16% 1,168.30% 1,897.18% 1,768.88% 1,824.76% 1,494.98% 2,782.56%
Free Cash Flow to Firm to Interest Expense		 -34.18 -137.74 -86.29 0.00 0.00 0.00 17.35 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 6.26 12.44 18.88 0.00 0.00 0.00 36.46 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 2.19 9.80 16.96 0.00 0.00 0.00 34.54 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.73 0.66 0.69 0.71 0.73 0.66 0.68 0.69 0.69 0.70 0.70
Accounts Receivable Turnover		 6.06 6.28 6.72 6.59 6.66 6.43 6.26 6.08 6.39 6.20 5.95
Inventory Turnover		 2.28 2.06 2.09 2.14 2.15 2.10 2.20 2.23 2.17 2.26 2.45
Fixed Asset Turnover		 7.59 7.52 7.71 8.15 8.57 8.38 8.58 8.63 8.79 9.19 9.34
Accounts Payable Turnover		 8.82 9.07 11.26 12.05 10.93 10.15 11.95 10.45 9.55 9.70 10.36
Days Sales Outstanding (DSO)		 60.22 58.11 54.30 55.35 54.77 56.81 58.34 60.07 57.08 58.89 61.31
Days Inventory Outstanding (DIO)		 159.88 177.13 174.32 170.24 169.74 173.49 165.73 163.64 168.26 161.61 149.10
Days Payable Outstanding (DPO)		 41.40 40.26 32.41 30.30 33.38 35.96 30.55 34.93 38.23 37.63 35.25
Cash Conversion Cycle (CCC)		 178.70 194.98 196.21 195.30 191.13 194.34 193.52 188.79 187.10 182.86 175.17
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 4,021 5,286 5,290 5,343 5,403 5,498 5,399 5,333 5,446 5,404 5,286
Invested Capital Turnover		 0.96 0.84 0.89 0.92 0.93 0.84 0.86 0.88 0.89 0.90 0.94
Increase / (Decrease) in Invested Capital		 465 1,654 1,533 1,481 1,382 213 108 -10 43 -94 -113
Enterprise Value (EV)		 31,955 31,527 33,055 32,904 22,676 26,085 29,763 28,523 36,120 33,722 32,616
Market Capitalization		 31,367 29,979 31,697 31,691 21,524 25,069 28,994 28,054 35,869 33,571 32,876
Book Value per Share		 $23.44 $25.52 $26.77 $28.11 $28.90 $30.47 $31.48 $33.11 $35.36 $35.78 $37.76
Tangible Book Value per Share		 $7.89 $2.62 $3.94 $5.49 $5.95 $7.42 $8.79 $10.46 $12.46 $13.69 $15.44
Total Capital		 4,228 5,539 5,518 5,571 5,612 5,709 5,637 5,571 5,873 5,926 6,219
Total Debt		 795 1,801 1,586 1,441 1,361 1,227 1,007 707 677 673 673
Total Long-Term Debt		 785 1,791 1,576 1,431 1,352 1,217 997 697 668 663 663
Net Debt		 588 1,547 1,358 1,213 1,152 1,016 769 469 251 151 -260
Capital Expenditures (CapEx)		 29 27 29 34 30 23 21 25 18 21 21
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 1,144 1,349 1,358 1,391 1,335 1,414 1,350 1,219 1,321 1,472 1,345
Debt-free Net Working Capital (DFNWC)		 1,351 1,602 1,586 1,619 1,544 1,624 1,588 1,457 1,747 1,994 2,278
Net Working Capital (NWC)		 1,341 1,592 1,576 1,609 1,534 1,614 1,578 1,447 1,737 1,984 2,268
Net Nonoperating Expense (NNE)		 11 5.34 9.07 -1.27 14 13 -0.67 19 3.10 -0.89 7.49
Net Nonoperating Obligations (NNO)		 588 1,547 1,358 1,213 1,152 1,016 769 469 251 151 -260
Total Depreciation and Amortization (D&A)		 44 46 53 55 53 53 55 55 54 56 52
Debt-free, Cash-free Net Working Capital to Revenue		 31.56% 35.85% 33.82% 32.95% 30.50% 31.39% 29.45% 26.01% 27.47% 29.88% 26.79%
Debt-free Net Working Capital to Revenue		 37.27% 42.58% 39.50% 38.34% 35.28% 36.05% 34.64% 31.10% 36.34% 40.48% 45.36%
Net Working Capital to Revenue		 37.00% 42.32% 39.25% 38.11% 35.06% 35.83% 34.43% 30.89% 36.13% 40.27% 45.16%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $1.44 $1.53 $1.58 $1.57 $1.49 $1.42 $2.04 $1.99 $2.12 $2.35 $2.49
Adjusted Weighted Average Basic Shares Outstanding		 146.43M 146.70M 146.91M 146.77M 147.08M 147.13M 146.96M 147.02M 146.86M 146.81M 146.72M
Adjusted Diluted Earnings per Share		 $1.43 $1.53 $1.58 $1.55 $1.49 $1.42 $2.04 $1.97 $2.11 $2.34 $2.48
Adjusted Weighted Average Diluted Shares Outstanding		 147.13M 147.41M 147.40M 147.46M 147.49M 147.55M 147.45M 147.55M 147.60M 147.48M 147.22M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 146.48M 146.91M 146.93M 147.07M 147.09M 147.09M 146.91M 146.93M 146.80M 146.87M 146.63M
Normalized Net Operating Profit after Tax (NOPAT)		 222 237 242 228 233 273 300 311 314 344 373
Normalized NOPAT Margin		 23.33% 22.94% 21.63% 20.35% 21.13% 23.48% 25.05% 25.46% 25.68% 26.81% 28.84%
Pre Tax Income Margin		 27.55% 26.48% 25.91% 24.67% 24.69% 22.31% 31.36% 29.25% 31.32% 32.63% 32.34%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 37.98 27.75 20.35 0.00 0.00 0.00 35.01 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 31.08 22.27 16.14 0.00 0.00 0.00 27.19 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 33.91 25.10 18.42 0.00 0.00 0.00 33.09 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 27.00 19.63 14.22 0.00 0.00 0.00 25.27 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 31.61% 31.11% 29.56% 29.04% 29.57% 30.80% 29.09% 27.78% 26.10% 23.82% 23.20%
Augmented Payout Ratio		 31.61% 31.11% 29.56% 29.04% 29.57% 36.42% 39.53% 42.47% 44.07% 41.84% 42.24%

Frequently Asked Questions About ResMed's Financials

When does ResMed's fiscal year end?

According to the most recent income statement we have on file, ResMed's financial year ends in June. Their financial year 2024 ended on June 30, 2024.

How has ResMed's net income changed over the last 9 years?

ResMed's net income appears to be on an upward trend, with a most recent value of $1.02 billion in 2024, rising from $352.89 million in 2015. The previous period was $897.56 million in 2023. Find out what analysts predict for ResMed in the coming months.

What is ResMed's operating income?
ResMed's total operating income in 2024 was $1.32 billion, based on the following breakdown:
  • Total Gross Profit: $2.66 billion
  • Total Operating Expenses: $1.34 billion
How has ResMed's revenue changed over the last 9 years?

Over the last 9 years, ResMed's total revenue changed from $1.68 billion in 2015 to $4.69 billion in 2024, a change of 179.1%.

How much debt does ResMed have?

ResMed's total liabilities were at $2.01 billion at the end of 2024, a 23.4% decrease from 2023, and a 237.8% increase since 2015.

How much cash does ResMed have?

In the past 9 years, ResMed's cash and equivalents has ranged from $147.13 million in 2019 to $821.94 million in 2017, and is currently $238.36 million as of their latest financial filing in 2024.

How has ResMed's book value per share changed over the last 9 years?

Over the last 9 years, ResMed's book value per share changed from 11.26 in 2015 to 33.11 in 2024, a change of 193.9%.


Related Companies

This page (NYSE:RMD) was last updated on 6/17/2025 by MarketBeat.com Staff
From Our Partners
Your Bank Account Is No Longer Safe
What If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...
Priority Gold | Sponsored
The End of Elon Musk…?
The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...
Brownstone Research | Sponsored
Utah’s New Oil Find
The Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...
Stansberry Research | Sponsored
July 2025 Rule Change to Impact Retirement Investors
There's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...
Premier Gold Co | Sponsored
Trump’s Exec Order #14154 could be a “Millionaire-Maker”
Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...
Paradigm Press | Sponsored
An AI run of epic proportions is only getting started
I just put together an urgent new presentation that you need to see right away. In short: I believe we are...
Timothy Sykes | Sponsored
When This Happens, You Don’t Wait. You Act.
This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...
Crypto Swap Profits | Sponsored
New Rule Hits in July — The Smart Money Already Moved
A little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...
American Alternative | Sponsored